| Code | 7936C | ||||||||||
| MA number | 44/0163/18-S | ||||||||||
| Product Form: | sol inj 1x3,5 mg/1,4 ml (liek.inj.skl.) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | STADA Arzneimittel AG, Germany | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 48 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Subcutaneous and intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(3) hybrid application |
| MA issued: | 22.05.2018 |
| PIL: |
PIL_Bortezomib STADA_10.2023.pdf
|
| SPC: |
SPC_Bortezomib STADA_01.2025.pdf
|
| Safety feature | Yes |
| Data update: | 14.01.2025 |
